Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in adults with warm autoimmune hemolytic anemia
NL-OMON59732Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nipocalimab in warm autoimmune hemolytic anemia (wAIHA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Durable hemoglobin response. Started Sep 2019; status: active, not recruiting.
02
Drugs
nipocalimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NL-OMON59732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59732.